Nanobiotix S.A., a clinical biotechnology company, announced its share capital and voting rights as of June 30, 2026. The company has 50,825,682 shares outstanding and a total of 54,486,890 theoretical voting rights, with 54,464,772 exercisable voting rights. This update is in line with French financial regulations and informs shareholders of the current capital structure. Nanobiotix continues to focus on its innovative nanotechnology platforms in oncology and other fields, maintaining transparency with investors as it advances its clinical programs.
Evercore ISI raised Ross Stores' price target to $276, suggesting a 12.5% upside from its current $245.36 price. The boost reflects strong expectations for Q2, with projected revenues of $6.10 billion (up 10.7%) and earnings per share of $1.92 (up 23...
Fabrinet is set to report strong Q3 2026 earnings with revenue forecasted at about $1.276 billion, a 41% increase year-over-year, driven by demand in Telecom and Data Center sectors. Earnings per share are expected to rise 45% to $3.81, reflecting ro...
Jernigan Capital, a REIT specializing in financing self-storage facilities, saw its stock rise over 11% to $24.00, reaching a new 52-week high. Analysts have a consensus "Moderate Buy" rating with an average 12-month price target of $27.50, suggestin...
CrowdStrike, a leading cybersecurity firm, has seen its stock price increase by 85% year-to-date, reaching a market cap over $220 billion. Investment firm Cowen & Co. reiterated a "Buy" rating and raised the price target to $235, citing strong financ...
Alpha Cognition Inc. reported a 71% quarter-over-quarter revenue increase to $6.0 million in Q2 2026, driven by strong demand for its ZUNVEYL product with 37% growth in bottles dispensed. Despite only 16% payer implementation, prescription and facili...
